Nuclear stiffness through lamin A/C overexpression differentially modulates chromosomal instability biomarkers
Biology of the Cell · 2025
DOI: 10.1111/boc.12001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology of the Cell, 2025. Verfasst von Mireia Bosch-Calvet und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Chromosomal Instability, Lamin Type A, Cell Nucleus. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agència de Gestió d'Ajuts Universitaris i de Recerca, University of Barcelona, Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación.
Abstract (Originalsprache)
Background
Information Mitosis is crucial for the faithful transmission of genetic material, and disruptions can result in chromosomal instability (CIN), a hallmark of cancer. CIN is a known driver of tumor heterogeneity and anti‐cancer drug resistance, thus highlighting the need to assess CIN levels in cancer cells to design effective targeted therapy. While micronuclei are widely recognized as CIN markers, we have recently identified the toroidal nucleus, a novel ring‐shaped nuclear phenotype arising as well from chromosome mis‐segregation.
Results
Here, we examined whether increasing nuclear envelope stiffness through lamin A/C overexpression could affect the formation of toroidal nuclei and micronuclei. Interestingly, lamin A/C overexpression led to an increase in toroidal nuclei while reducing micronuclei prevalence. We demonstrated that chromatin compaction and nuclear stiffness drive the formation of toroidal nuclei. Furthermore, inhibition of autophagy and lysosomal function elevated the frequency of toroidal nuclei without affecting the number of micronuclei in the whole cell population. We demonstrated that this divergence between the two CIN biomarkers is independent of defects in lamin A processing. Conclusions and Significance These findings uncover a complex interplay between nuclear architecture and levels of CIN, advancing our understanding of the mechanisms supporting genomic stability and further contributing to cancer biology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Institut de Recerca Sant Joan de Déu (IRSJD), Barcelona, Spain.
- Cancer Science Programme, Laboratory of Pediatric Cancer Epigenetics, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.
ORCID-Profile: Mireia Bosch-Calvet, Alejandro Pérez-Venteo, Alex Cebria-Xart, Marta Garcia-Cajide, Caroline Mauvezin
Förderung
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- University of Barcelona
- Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación
- Ramon y Cajal fellowship
- Asociación Española Contra el Cáncer AECC
- Universitat de Barcelona
Zitieren
APA
Bosch-Calvet, M., Pérez-Venteo, A., Cebria-Xart, A., Garcia-Cajide, M., & Mauvezin, C. (2025). Nuclear stiffness through lamin A/C overexpression differentially modulates chromosomal instability biomarkers. Biology of the Cell. https://doi.org/10.1111/boc.12001
Vancouver
Bosch-Calvet M, Pérez-Venteo A, Cebria-Xart A, Garcia-Cajide M, Mauvezin C. Nuclear stiffness through lamin A/C overexpression differentially modulates chromosomal instability biomarkers. Biology of the Cell. 2025. doi:10.1111/boc.12001
BibTeX
@article{BoschCalvet2025,
author = {Bosch-Calvet, Mireia and Pérez-Venteo, Alejandro and Cebria-Xart, Alex and Garcia-Cajide, Marta and Mauvezin, Caroline},
title = {Nuclear stiffness through lamin A/C overexpression differentially modulates chromosomal instability biomarkers},
journal = {Biology of the Cell},
year = {2025},
doi = {10.1111/boc.12001}
}
EUVIMED